Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2024 to Q4 2025

Type / Class
Equity / Voting Common Stock, par value $0.0001 per share
Symbol
ALGS on Nasdaq
Shares outstanding
5,354,981
Price per share
$8.06
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
2,811,051
Total reported value
$26,190,276
% of total 13F portfolios
0%
Share change
+159,403
Value change
+$1,301,467
Number of holders
39
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Alyeska Investment Group, L.P. 10% $2,809,000 530,000 Alyeska Investment Group, L.P. 31 Mar 2025
Sio Capital Management, LLC 5.5% -0.6% $3,104,058 -$184,800 335,937 -5.6% Sio Capital Management, LLC 31 Dec 2025
Woodline Partners LP 5.4% -37% $2,671,922 -$1,654,237 289,169 -38% Woodline Partners LP 31 Dec 2025
EcoR1 Capital, LLC 3.9% $1,116,360 210,634 EcoR1 Capital, LLC 31 Mar 2025
Adage Capital Management, L.P. 3.9% -61% $1,514,100 -$829,150 210,000 -35% Adage Capital Management, L.P. 30 Jun 2025
ARMISTICE CAPITAL, LLC 5% $998,721 188,438 Armistice Capital, LLC 31 Dec 2024
BLATT LAWRENCE 3.2% $930,198 175,509 Lawrence M. Blatt, Ph.D. 10 Mar 2025

As of 31 Dec 2025, 39 institutional investors reported holding 2,811,051 shares of Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS). This represents 52% of the company’s total 5,354,981 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Deep Track Capital, LP 8.3% 444,110 0% 0.09% $4,139,105
Alyeska Investment Group, L.P. 7.7% 412,000 0% 0.01% $3,839,840
Sio Capital Management, LLC 6.3% 335,937 0% 0.52% $3,130,933
Woodline Partners LP 5.4% 289,169 -38% 0.01% $2,695,055
MARSHALL WACE, LLP 5% 268,664 0% $2,503,949
VANGUARD GROUP INC 3.7% 200,395 +17% 0% $1,867,682
SummitTX Capital, L.P. 2.6% 139,424 0.04% $1,299,432
RENAISSANCE TECHNOLOGIES LLC 1.6% 85,444 +55% 0% $796,338
BAKER BROS. ADVISORS LP 1.6% 83,055 0% 0% $774,073
TWO SIGMA INVESTMENTS, LP 1.5% 80,649 +107% 0% $751,649
HHLR ADVISORS, LTD. 1.4% 76,247 0% 0.02% $710,622
Verition Fund Management LLC 1.3% 71,254 0% $664,087
LPL Financial LLC 1.2% 66,000 +20% 0% $615,120
CITADEL ADVISORS LLC 0.97% 51,834 +403% 0% $483,093
GEODE CAPITAL MANAGEMENT, LLC 0.89% 47,741 +1.4% 0% $445,136
JANE STREET GROUP, LLC 0.45% 24,293 0% $226,411
XTX Topco Ltd 0.43% 23,053 0.01% $214,854
AlphaQuest LLC 0.26% 13,876 +105% 0.01% $129,324
BANK OF AMERICA CORP /DE/ 0.24% 13,108 +585% 0% $122,166
BlackRock, Inc. 0.24% 13,040 0% 0% $121,533
TWO SIGMA ADVISERS, LP 0.24% 13,000 0% $121,160
DRW Securities, LLC 0.22% 11,950 0.01% $111,374
HRT FINANCIAL LP 0.21% 11,374 0% $106,000
Rockefeller Capital Management L.P. 0.19% 10,000 +900% 0% $93,200
NorthCrest Asset Manangement, LLC 0.19% 10,000 0% 0% $84,100

Institutional Holders of Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,811,051 $26,190,276 +$1,301,467 $9.32 39
2025 Q3 2,651,648 $25,986,937 +$21,301 $9.80 33
2025 Q2 2,706,213 $19,511,284 -$4,851,101 $7.21 37
2025 Q1 3,295,608 $27,078,858 +$7,676,587 $8.25 35
2024 Q4 1,619,199 $64,508,583 +$11,813,062 $39.84 33
2024 Q3 1,692,019 $14,651,229 +$14,572,683 $8.66 27